HomeAI · summaries
Storia in 9 fonti
Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook
Lilly's Foundayo and Zepbound gain CVS Caremark formulary coverage, expanding access for 90 million members at $25 monthly co-pays.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
CVS obesity drug deal puts Lilly on equal footing with Novo
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
- ·
morningstar.com
Foundayo and Zepbound now covered for millions of Americans
Foundayo and Zepbound now covered for millions of Americans
